Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
URGN
HoldHot AirUroGen Pharma Ltd. · Healthcare · United States · $2.1B · Avg Vol: $40M/d
COMPANY DESCRIPTION
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for urological cancers. The company's competitive moat is its proprietary RTGel technology, a sustained-release hydrogel that overcomes the bladder's natural clearance mechanisms to deliver localized treatment. It operates as a specialized niche player in the uro-oncology market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 64.4M | 82.7M | 90.4M | 109.8M | 19.5% | 188.7M | 322.2M | 541.5M | 122.1% |
| EPS | -2.27 | -3.55 | -2.96 | -3.19 | — | -1.94 | — | — | — |
| Shares | 48.7M | 32.5M | 42.2M | 48.4M | -0.8% | 48.9M | — | — | — |
| Debt | 99.1M | 99.4M | 123.4M | 128.3M | 9.0% | 196.1M | — | — | — |
| Equity | -89.4M | -65.2M | -8.8M | -105.5M | — | — | — | — | — |
| Op CF | -87.6M | -76.4M | -96.8M | -162.4M | — | -158.9M | — | — | — |
| Inv CF | 1.1M | -1.0M | -20.6M | 61.6M | — | — | — | — | — |
| Fin CF | 97.1M | 116.9M | 194.6M | 39.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of URGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| URGN | UroGen Pharma Ltd.(you) | $2.1B | 51 | Hold |
| ADMA | ADMA Biologics, Inc. | $2.1B | 53 | Hold |
| SEPN | Septerna, Inc. | $1.8B | 52 | Hold |
| VCEL | Vericel Corporation | $2.1B | 56 | Hold |
| SRPT | Sarepta Therapeutics, Inc. | $2.2B | 46 | Hold |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.0B | 50 | Hold |
| SLS | SELLAS Life Sciences Group, Inc. | $2.7B | 44 | Hold |
| OMER | Omeros Corporation | $1.3B | 48 | Hold |
| FTRE | Fortrea Holdings Inc. | $1.8B | 60 | Hold |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.1B | 44 | Hold |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.1%